129 related articles for article (PubMed ID: 7553660)
1. Are CD44 variant isoforms involved in human tumour progression?
Günthert U; Stauder R; Mayer B; Terpe HJ; Finke L; Friedrichs K
Cancer Surv; 1995; 24():19-42. PubMed ID: 7553660
[TBL] [Abstract][Full Text] [Related]
2. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer.
Friedrichs K; Franke F; Lisboa BW; Kügler G; Gille I; Terpe HJ; Hölzel F; Maass H; Günthert U
Cancer Res; 1995 Nov; 55(22):5424-33. PubMed ID: 7585612
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation.
Terpe HJ; Störkel S; Zimmer U; Anquez V; Fischer C; Pantel K; Günthert U
Am J Pathol; 1996 Feb; 148(2):453-63. PubMed ID: 8579108
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice.
Fichtner I; Dehmel A; Naundorf H; Finke LH
Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216
[TBL] [Abstract][Full Text] [Related]
5. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
6. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas.
Terpe HJ; Koopmann R; Imhof BA; Günthert U
J Pathol; 1994 Oct; 174(2):89-100. PubMed ID: 7525912
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter.
Masuda M; Takano Y; Iki M; Makiyama K; Noguchi S; Hosaka M
J Urol; 1999 Mar; 161(3):805-8; discussion 808-9. PubMed ID: 10022688
[TBL] [Abstract][Full Text] [Related]
8. CD44 is an independent prognostic factor in conventional renal cell carcinomas.
Paradis V; Ferlicot S; Ghannam E; Zeimoura L; Blanchet P; Eschwége P; Jardin A; Benoît G; Bedossa P
J Urol; 1999 Jun; 161(6):1984-7. PubMed ID: 10332486
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
11. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
12. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
Reeder JA; Gotley DC; Walsh MD; Fawcett J; Antalis TM
Cancer Res; 1998 Aug; 58(16):3719-26. PubMed ID: 9721884
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CD44 molecule in renal cell carcinoma.
Lucin K; Matusan K; Dordević G; Stipić D
Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803
[TBL] [Abstract][Full Text] [Related]
14. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type.
Ariza A; Mate JL; Isamat M; López D; Von Uexküll-Güldeband C; Rosell R; Fernández-Vasalo A; Navas-Palacios JJ
J Pathol; 1995 Dec; 177(4):363-8. PubMed ID: 8568590
[TBL] [Abstract][Full Text] [Related]
15. Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.
de la Torre M; Heldin P; Bergh J
Anticancer Res; 1995; 15(6B):2791-5. PubMed ID: 8669866
[TBL] [Abstract][Full Text] [Related]
16. CD44 splice variants: expression during lymphocyte activation and tumor progression.
Pals ST; Koopman G; Heider KH; Griffioen A; Adolf GR; Van den Berg F; Ponta H; Herrlich P; Horst E
Behring Inst Mitt; 1993 Aug; (92):273-7. PubMed ID: 7504454
[TBL] [Abstract][Full Text] [Related]
17. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression.
Li H; Guo L; Li JW; Liu N; Qi R; Liu J
Int J Oncol; 2000 Nov; 17(5):927-32. PubMed ID: 11029494
[TBL] [Abstract][Full Text] [Related]
18. Invasive cribriform breast carcinomas in patients with grade 1 and stage IIA (T2 N0 M0) breast cancer strongly express the v3 and v6, but not the v4 isoforms of the metastatic marker CD44.
Saleh F; Reno W
Neoplasma; 2008; 55(3):246-55. PubMed ID: 18348657
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas.
Satoh K; Shimosegawa T; Koizumi M; Toyota T
Anticancer Res; 1997; 17(1A):215-9. PubMed ID: 9066654
[TBL] [Abstract][Full Text] [Related]
20. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.
Miyake H; Eto H; Arakawa S; Kamidono S; Hara I
J Urol; 2002 Mar; 167(3):1282-7. PubMed ID: 11832714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
